Skip to main content

Market Overview

Mesoblast Investors Shrug Off Positive Phase 2a Trial Data


Shares of Mesoblast limited (ADR) (NASDAQ: MESO) were trading lower by more than 1 percent on Friday despite announcing earlier in the day positive Phase 2a trial data.

Mesoblast is engaged in the development of adult stem cell technology platforms. The company announced that results from a Phase 2a trial in patients with post-traumatic knee injury to their ACL showed that a single intra-articular injection of its mesenchymal precursor cell product candidate, known as MPC-75-IA, resulted in improvement in pain, function, cartilage thickness and joint structure among the 17 patients.

The results of Mesoblast's study will be presented at the 2016 Osteoarthritis Research Society International (OARSI) World Congress in Amsterdam, The Netherlands.

Professor Flavia Cicuttini, Head Musculoskeletal Unit, Department of Epidemiology and Preventive Medicine School of Public Health and Preventive Medicine at Monash University, Australia said: "These results are remarkable in that we were able to demonstrate significant improvements in patient symptoms and joint structure. We look forward to conducting a larger Phase 2/3 trial to confirm the observed significant long-term benefits in pain, function, and quality of life."


Related Articles (MESO)

View Comments and Join the Discussion!

Posted-In: ACL Injury Mesoblast MPC-75-IA Stem CellNews

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at